[1]张 解,马 聪,孙婷婷,等.血清单核细胞趋化蛋白1、高级氧化蛋白产物、尿微量白蛋白/肌酐比值与慢性肾衰竭患者血液透析治疗预后的相关性[J].陕西医学杂志,2025,54(1):76-79，92.[doi:DOI:10.3969/j.issn.1000-7377.2025.01.014]
　ZHANG Jie,MA Cong,SUN Tingting,et al.Correlation between serum MCP-1,AOPP,UACr and prognosis of patients with chronic renal failure after hemodialysis treatment[J].,2025,54(1):76-79，92.[doi:DOI:10.3969/j.issn.1000-7377.2025.01.014]
点击复制

血清单核细胞趋化蛋白1、高级氧化蛋白产物、尿微量白蛋白/肌酐比值与慢性肾衰竭患者血液透析治疗预后的相关性
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年1期
页码:
76-79，92
栏目:
临床研究
出版日期:
2025-01-05

文章信息/Info

Title:
Correlation between serum MCP-1,AOPP,UACr and prognosis of patients with chronic renal failure after hemodialysis treatment
作者:
张 解1; 马 聪1; 孙婷婷1; 张 雪2
(1.青岛市胶州中心医院血液净化中心,山东 青岛 266300; 2.青岛市胶州中心医院肾病风湿免疫科,山东 青岛 266300)
Author(s):
ZHANG Jie; MA Cong; SUN Tingting; ZHANG Xue
(Blood Purification Center,Qingdao Jiaozhou Central Hospital,Qingdao 266300,China)
关键词:
单核细胞趋化蛋白1;  高级氧化蛋白产物;  尿微量白蛋白/肌酐比值;  慢性肾衰竭;  血液透析;  预后
Keywords:
MCP-1;  AOPP;  UACr;  Chronic kidney failure;  Hemodialysis;  Prognosis
分类号:
R 692.5
DOI:
DOI:10.3969/j.issn.1000-7377.2025.01.014
文献标志码:
A
摘要:
目的:探讨血清单核细胞趋化蛋白1(MCP-1)、高级氧化蛋白产物(AOPP)、尿微量白蛋白/肌酐比值(UACr)与慢性肾衰竭(CRF)患者血液透析治疗预后的关系。方法:选择116例经血液透析治疗的CRF患者为研究对象,以预后情况作为分组标准,即预后良好组和预后不良组,分别检测两组血清MCP-1、AOPP、尿UACr水平,分析其与CRF血液透析治疗预后的关系,受试者工作特征曲线(ROC)分析三者对预后的预测价值。结果:116例CRF血液透析治疗患者中预后不良42例(36.21%),预后良好74例(63.79%)。不同预后患者在年龄、合并症和血白蛋白(ALB)、MCP-1、AOPP、UACr水平上比较,差异有统计学意义(均P<0.05)。血清MCP-1、AOPP、UACr水平与CRF血液透析预后不良呈正相关(均P<0.05)。MCP-1、AOPP、UACr对血液透析治疗预后预测的曲线下面积(AUC)为0.875(95%CI:0.718～3.921),灵敏度87.50%,特异度90.79%(均P<0.05)。结论:CRF血液透析治疗预后不良患者血清MCP-1、AOPP水平和UACr值升高,三者与血液透析治疗预后关系密切。
Abstract:
Objective:To investigate the relationship between serum monocyte chemotactic protein 1(MCP-1),advanced oxidized protein product(AOPP),urinary microalbumin/creatinine ratio(UACr)and the prognosis of patients with chronic renal failure(CRF)after hemodialysis treatment.Methods:A total of 116 patients with CRF undergoing hemodialysis were selected as the study objects,and the prognosis was used as the grouping criterion,that is,the good prognosis group and the poor prognosis group.Serum MCP-1,AOPP and urine UACr levels of the two groups were measured respectively,and the relationship between them and the prognosis of CRF hemodialysis treatment was analyzed.Receiver operating characteristic curve(ROC)was used to analyze the prognostic value of the three factors.Results:Among 116 patients treated with CRF hemodialysis,42 cases(36.21%)had poor prognosis and 74 cases(63.79%)had good prognosis.There were significant differences in age,comorbidities,ALB,MCP-1,AOPP and UACr among patients with different prognosis(all P<0.05).Serum MCP-1,AOPP and UACr levels were positively correlated with poor prognosis of CRF hemodialysis(all P<0.05).The area under the curve(AUC)of MCP-1,AOPP and UACr for prognosis of hemodialysis treatment was 0.875(95%CI:0.718～3.921),the sensitivity was 87.50%,and the specificity was 90.79%(all P<0.05).Conclusion:The serum levels of MCP-1,AOPP and UACr are increased in patients with poor prognosis after hemodialysis treatment of CRF,which are closely related to the prognosis.

参考文献/References:

[1] 刘文君,王亿平,吕伟,等.益气护肾方佐治慢性肾衰竭3～5期肾气虚夹瘀临床研究[J].陕西中医,2024,45(8):1056-1060.
[2] 李丹,谷学梅.血液透析用于慢性肾功能衰竭合并急性心力衰竭临床治疗的价值评价[J].陕西医学杂志,2018,47(9):1161-1163.
[3] KANDA T,ARIMA S,SASAKI-TANAKA R,et al.Severe hepatitis E virus genotype 3b in a patient with alcoholassociated liver disease:A case report[J].Med Int(Lond),2024,4(3):22.
[4] 王军涛,魏晓颖,王晓阳.参乌益肾片联合复方α酮酸片治疗慢性肾衰竭的临床研究[J].现代药物与临床,2023,38(1):169-172.
[5] 李娟,方敬爱.益肾胶囊对糖尿病肾病大鼠肾组织SOCS3、TGF-β1、MCP-1表达的影响[J].中国中西医结合肾病杂志,2011,12(4):291-294.
[6] 来利红,杨兰,汪晓东,等.血清TGF-β1、MCP-1在慢性心力衰竭患者合并早期肾功能衰竭中的诊断价值[J].中国循证心血管医学杂志,2022,14(2):194-196,201.
[7] 卢海源,蒋海涛,史国辉,等.老年慢性肾衰竭维持性血液透析患者褪黑素、AOPP水平与骨质疏松症的关系研究[J].河北医科大学学报,2022,43(7):763-767.
[8] 钱莹,李砚民,陈永强.海昆肾喜胶囊对慢性肾衰竭患者氧化应激影响的临床观察[J].上海中医药杂志,2018,52(4):59-61.
[9] 陈月梅,张春莹,龙婷婷,等.随机尿蛋白、尿蛋白/肌酐比值及尿微量白蛋白/肌酐比值在早期糖尿病肾病中应用价值[J].临床军医杂志,2023,51(4):362-365,369.
[10] 王彩蕊,马彩云,任凤学.尿微量白蛋白与尿肌酐比值与冠心病患者冠状动脉狭窄程度的关系分析[J].实用心脑肺血管病杂志,2023,31(7):62-65.
[11] 蔡乐山.早期慢性肾衰竭患者尿微量白蛋白/尿肌酐与转铁蛋白水平变化及临床意义[J].中国实验诊断学,2018,22(10):1764-1765.
[12] 中华中医药学会.慢性肾衰竭诊疗指南[J].中国中医药现代远程教育,2011,9(9):132-133.
[13] 谢嘉平,徐维茜,杨洁珂,等.血液透析糖尿病患者自体动静脉内瘘失功影响因素及预测模型临床研究[J].陕西医学杂志,2024,53(5):641-645.
[14] 王文静,赵艳龙,曾晓荣,等.维持性血液透析患者微炎症状态中医诊疗进展[J].陕西中医,2023,44(4):541-544.
[15] MUNSHI R,TORRES A H,RAMIREZ-PRECIADO B,et al.Transition of care:Lessons from the Standardizing Care to Improve Outcomes in Pediatric End Stage Renal Disease(SCOPE)dialysis collaborative[J].Pediatr Nephrol,2024,39(5):1551-1557.
[16] 沈阳,秦明明,张洪旭.终末期肾病维持性血液透析患者的RDW、NLR水平变化及其预后分析[J].中国医药导报,2021,18(3):71-74.
[17] CHO I,CHUNG K H,KIM Y,et al.Baicalein inhibits IL-1β-induced extracellular matrix degradation with decreased MCP-1 expression in primary rat chondrocytes[J].Toxicol Res,2024,40(2):237-246.
[18] JIA S,SI R,LIU G,et al.Diosgenin protects against cationic bovine serum albumin-induced membranous glomerulonephritis by attenuating oxidative stress and renal inflammation via the NF-κB pathway[J].Pharm Biol,2024,62(1):285-295.
[19] FANG H,YANG T,ZHOU B,et al.(Pro)Renin receptor decoy peptide pro20 protects against oxidative renal damage induced by advanced oxidation protein products[J].Molecules,2023,28(7):3017.
[20] 孔淑君,陈卫东.慢性肾脏病氧化应激的研究进展[J].国际泌尿系统杂志,2020,40(4):759-762.
[21] 计小静,王静一.CKD 5期维持性血液透析患者左室舒张功能障碍的危险因素研究[J].保健医学研究与实践,2023,20(9):45-48.
[22] 吴忠.血清肌酐联合尿微量白蛋白/肌酐比值在冠心病合并肾衰竭中的临床意义[J].河北医药,2022,44(1):104-106.
[23] 李亚迪,钟莹莹.血清MCP-1、HMGB-1水平与慢性肾衰竭血液透析治疗患者预后情况的相关性分析[J].临床医学工程,2022,29(10):1475-1476.
[24] 华佳,张悦,李瑞雪,等.慢性肾功能衰竭的腹膜透析患者短期预后不良的影响因素分析[J].国际泌尿系统杂志,2023,43(4):693-697.
[25] 谢依嶷,赵志权,宁燕虹,等.慢性肾病患者血液透析治疗后造影剂肾病的发生情况及其与UACR、CM/eGFR水平和MACE发生率的关系[J].国际泌尿系统杂志,2022,42(4):702-705.
[26] 张文丰.慢性肾衰竭血液透析患者AOPP、OX-LDL水平表达意义及相关性分析[J].黑龙江医药,2022,35(4):776-779.

备注/Memo

备注/Memo:
基金项目:山东省卫生健康委员会科研项目(2021KY01332)
更新日期/Last Update: 2025-01-06